Results 11 to 20 of about 51,825 (261)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure
Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
doaj   +2 more sources

Novel cardiac myosin inhibitor for hypertrophic cardiomyopathy. [PDF]

J Gen Physiol
New RLC-1 small-molecule inhibits actomyosin interactions, reduces contractile force, and speeds up myosin cross-bridge kinetics.
Szczesna-Cordary D.
europepmc   +3 more sources

Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy

The Egyptian Heart Journal
Background Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of ...
Ikponmwosa Jude Ogieuhi, Victor Oluwatomiwa Ajekiigbe, Boluwaduro Abasiekem Adeyemi, Bright Nwatamole, Komolafe Babajide Ayodeji, Oshomoh Mark-Anthony Ugiomoh, Temiloluwa Adebayo Odeniyi, Adewunmi Akingbola, Efosa Peace Iyawe, Olabode Olawale Oladejo, Motunrayo Oluwatoyosi Lawal, Nathnael Abera Woldehana, Ifeoluwa Sandra Bakare, Adejumo Temilade Patience, Grace Chinenye Okoro   +14 more
doaj   +3 more sources

Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives. [PDF]

Cureus
Mavacamten is a first-in-class, selective allosteric inhibitor of cardiac myosin adenosine triphosphatase (ATPase) that has emerged as a novel therapeutic option for patients with symptomatic hypertrophic obstructive cardiomyopathy (HOCM) who remain refractory to conventional therapy, such as beta-blockers and calcium channel blockers.
Ramadan MM, Al-Najjar RA, Abady RS, Obaid HA, Mostafa YA, Al-Obeid MT, Elmahal M.   +6 more
europepmc   +3 more sources

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
doaj   +2 more sources

Mechanisms of a novel regulatory light chain-dependent cardiac myosin inhibitor. [PDF]

J Gen Physiol
Hypertrophic cardiomyopathy (HCM) is a genetic disease of the heart characterized by thickening of the left ventricle (LV), hypercontractility, and impaired relaxation. HCM is caused primarily by heritable mutations in sarcomeric proteins, such as β myosin heavy chain.
Kooiker K, Gan QF, Yu M, Sa N, Mohran S, Cheng Y, Flint G, Neys S, Gao C, Nissen D, McMillen T, Asencio A, Ma W, Irving TC, Moussavi-Harami F, Regnier M.   +15 more
europepmc   +3 more sources

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]

Int J Mol Sci
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes. Conventional treatments, such as the use of beta blockers or calcium channel blockers, focus on symptomatic control but do not address the underlying ...
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.   +7 more
europepmc   +3 more sources

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. [PDF]

Nat Cardiovasc Res
AbstractHypertrophic cardiomyopathy (HCM) is an inherited disease of the sarcomere resulting in excessive cardiac contractility. The first-in-class cardiac myosin inhibitor, mavacamten, improves symptoms in obstructive HCM. Here we present aficamten, a selective small-molecule inhibitor of cardiac myosin that diminishes ATPase activity by strongly ...
Hartman JJ, Hwee DT, Robert-Paganin J, Chuang C, Chin ER, Edell S, Lee KH, Madhvani R, Paliwal P, Pernier J, Sarkar SS, Schaletzky J, Schauer K, Taheri KD, Wang J, Wehri E, Wu Y, Houdusse A, Morgan BP, Malik FI.   +19 more
europepmc   +4 more sources

Novel Cardiac Myosin Inhibitor Therapy for Hypertrophic Cardiomyopathy in Adults: A Contemporary Review. [PDF]

Am J Cardiovasc Drugs
Hypertrophic cardiomyopathy (HCM) affects as many as 1 in 200 people in the adult population globally. Patients may present with exertional dyspnea, presyncope or syncope, atrial and ventricular arrhythmias, heart failure, and even sudden cardiac death.
Kalinski JK, Xu B, Boyd R, Tasseff N, Rutkowski K, Ospina S, Smedira N, Thamilarasan M, Popovic ZB, Desai MY.   +9 more
europepmc   +3 more sources

Genetically Encoded Biosensors Reveal PKA Hyperphosphorylation on the Myofilaments in Rabbit Heart Failure [PDF]

, 2016
RATIONALE: In heart failure, myofilament proteins display abnormal phosphorylation, which contributes to contractile dysfunction. The mechanisms underlying the dysregulation of protein phosphorylation on myofilaments is not clear.
Barbagallo, Federica, Bers, Donald, Bossuyt, Julie, Ferrier, William, Fu, Qin, Ginsburg, Kenneth S., Isidori, Andrea, Li, Minghui, Naro, Fabio, Patel, Hemal H., Reddy, Gopireddy R., Shi, Qian, Wang, Qingtong, West, Toni, Xiang, Yang K., Xu, Bing   +15 more
core   +1 more source